Suzuki T, Maruyama D, Miyagi-Maeshima A, et al. - This study was undertaken to evaluate the clinicopathological characteristics and outcomes of patients with primary refractory diffuse large B-cell lymphoma (DLBCL). Researchers recruited a total of 69 consecutive patients with primary refractory DLBCL who were treated at our institution, were categorized as partial responders (partial response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone [R-CHOP] or relapse within 6 months of R-CHOP) (n = 41) or primary progressors (no response to R-CHOP) (n = 28). Using the Kaplan–Meier method and compared using the log-rank test, survival curves were constructed. They distinguished a subgroup of patients with primary refractory DLBCL who may not benefit from current treatment strategies. There is a need for further treatment development to improve the outcomes of these patients.